https://syn2bio.pl/en/synektik-edges-closer-to-demerger-as-syn2bio-files-prospectus-with-knf/2026-03-12T08:45:37+01:00https://syn2bio.pl/en/synektik-one-step-closer-to-planned-division/2026-03-12T08:46:57+01:00https://syn2bio.pl/en/synektik-plans-to-devide-it-is-spinning-off-the-cardiotracer-research-project-into-a-new-company-which-will-also-be-listed-on-the-wse/2026-03-12T08:50:49+01:00https://syn2bio.pl/en/knf-has-approved-the-syn2bio-prospectus-the-debut-on-the-wse-is-planned-for-april/2026-03-12T18:07:42+01:00https://syn2bio.pl/en/synektik-shareholders-have-unanimously-approved-the-division-of-the-company-and-spinoff-of-the-cardiotracer-project-to-syn2bio/2026-03-19T15:15:53+01:00https://syn2bio.pl/en/the-division-of-synektik-is-complete-the-court-has-registeredthe-issue-of-syn2bio-shares/2026-03-30T13:53:08+02:00